BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 22691503)

  • 1. Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer.
    Jadvar H; Desai B; Ji L; Conti PS; Dorff TB; Groshen SG; Gross ME; Pinski JK; Quinn DI
    Clin Nucl Med; 2012 Jul; 37(7):637-43. PubMed ID: 22691503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
    Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
    J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
    Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
    J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-Specific Antigen and Prostate-Specific Antigen Kinetics in Predicting
    Yoon J; Ballas L; Desai B; Jadvar H
    World J Nucl Med; 2017; 16(3):229-236. PubMed ID: 28670183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
    Castellucci P; Fuccio C; Rubello D; Schiavina R; Santi I; Nanni C; Allegri V; Montini GC; Ambrosini V; Boschi S; Martorana G; Marzola MC; Fanti S
    Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution.
    Marzola MC; Chondrogiannis S; Ferretti A; Grassetto G; Rampin L; Massaro A; Castellucci P; Picchio M; Al-Nahhas A; Colletti PM; Marcolongo A; Rubello D
    Clin Nucl Med; 2013 Jan; 38(1):e26-32. PubMed ID: 23242060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Comparison of
    Fourquet A; Rosenberg A; Mena E; Shih JJ; Turkbey B; Blain M; Bergvall E; Lin F; Adler S; Lim I; Madan RA; Karzai F; Gulley JL; Dahut WL; Wood BJ; Chang R; Levy E; Choyke PL; Lindenberg L
    J Nucl Med; 2022 May; 63(5):735-741. PubMed ID: 34475237
    [No Abstract]   [Full Text] [Related]  

  • 9. Positron emission tomography for prostate, bladder, and renal cancer.
    Schöder H; Larson SM
    Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases.
    Iagaru A; Young P; Mittra E; Dick DW; Herfkens R; Gambhir SS
    Clin Nucl Med; 2013 Jul; 38(7):e290-6. PubMed ID: 23455520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of osseous metastasis by 18F-NaF/18F-FDG PET/CT versus CT alone.
    Sampath SC; Sampath SC; Mosci C; Lutz AM; Willmann JK; Mittra ES; Gambhir SS; Iagaru A
    Clin Nucl Med; 2015 Mar; 40(3):e173-7. PubMed ID: 25140557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
    Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
    J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidental abnormal FDG uptake in the prostate on 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography scans.
    Kang PM; Seo WI; Lee SS; Bae SK; Kwak HS; Min K; Kim W; Kang DI
    Asian Pac J Cancer Prev; 2014; 15(20):8699-703. PubMed ID: 25374193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
    Castellucci P; Ceci F; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Pettinato C; Celli M; Lodi F; Fanti S
    J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy.
    Schöder H; Herrmann K; Gönen M; Hricak H; Eberhard S; Scardino P; Scher HI; Larson SM
    Clin Cancer Res; 2005 Jul; 11(13):4761-9. PubMed ID: 16000572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective Evaluation of
    Song H; Harrison C; Duan H; Guja K; Hatami N; Franc BL; Moradi F; Aparici CM; Davidzon GA; Iagaru A
    J Nucl Med; 2020 Apr; 61(4):546-551. PubMed ID: 31628216
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective comparison of combined 18F-FDG and 18F-NaF PET/CT vs. 18F-FDG PET/CT imaging for detection of malignancy.
    Lin FI; Rao JE; Mittra ES; Nallapareddy K; Chengapa A; Dick DW; Gambhir SS; Iagaru A
    Eur J Nucl Med Mol Imaging; 2012 Feb; 39(2):262-70. PubMed ID: 22065013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Prospective Comparison of
    Harmon SA; Bergvall E; Mena E; Shih JH; Adler S; McKinney Y; Mehralivand S; Citrin DE; Couvillon A; Madan RA; Gulley JL; Mease RC; Jacobs PM; Pomper MG; Turkbey B; Choyke PL; Lindenberg ML
    J Nucl Med; 2018 Nov; 59(11):1665-1671. PubMed ID: 29602821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of 13N-ammonia and 18F-FDG whole-body PET/CT on the same day for diagnosis of advanced prostate cancer.
    Yi C; Yu D; Shi X; Zhang X; Luo G; He Q; Zhang X
    Nucl Med Commun; 2016 Mar; 37(3):239-46. PubMed ID: 26588068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.